Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combi-TED: Tedopi Plus Docetaxel or Nivolumab in Advanced NSCLC
NCT04884282Phase 2Active, not recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Oct 2021
- Primary completion
- Sep 2027
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Tedopi in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: 1-year Survival Rate. Started Oct 2021; status: active, not recruiting.
02
Drugs
Tedopi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04884282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884282.